BS_92VDQ0NE
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 359.1327201051248
- age_years
- 2.54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.480
- SPERMATOGENESIS+0.287
- PANCREAS_BETA_CELLS+0.279
- APICAL_SURFACE+0.263
- MYOGENESIS+0.187
- BILE_ACID_METABOLISM+0.135
- HEDGEHOG_SIGNALING+0.124
- ESTROGEN_RESPONSE_EARLY+0.088
- ESTROGEN_RESPONSE_LATE+0.083
- HEME_METABOLISM+0.042
Top 10 suppressed
- MYC_TARGETS_V1-0.664
- MYC_TARGETS_V2-0.630
- E2F_TARGETS-0.590
- DNA_REPAIR-0.581
- UNFOLDED_PROTEIN_RESPONSE-0.578
- G2M_CHECKPOINT-0.566
- OXIDATIVE_PHOSPHORYLATION-0.508
- INTERFERON_GAMMA_RESPONSE-0.445
- MTORC1_SIGNALING-0.440
- INTERFERON_ALPHA_RESPONSE-0.436
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K5802F84 | pilocytic astrocytoma | — | 0.981 |
| 2 | BS_CQSAJ7BF | DNET | — | 0.976 |
| 3 | BS_KPT2WPHW | Ganglioglioma | — | 0.976 |
| 4 | BS_ZR96A4FH | DNET | — | 0.964 |
| 5 | BS_QC3XCE6X | low-grade glioma | — | 0.963 |
| 6 | BS_QV51J756 | Ganglioglioma | — | 0.962 |
| 7 | BS_C7N3J4NW | high-grade glioma | — | 0.962 |
| 8 | BS_JXNZYGCR | DNET | — | 0.962 |
| 9 | BS_6MY8W3H0 | DNET | — | 0.959 |
| 10 | BS_0T17SY47 | low-grade glioma | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.480 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.287 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.279 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.263 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.187 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.135 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.124 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.088 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.083 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.042 | Temsirolimus | — uncovered |